GLP-1 demand is expanding beyond diabetes into obesity and cardiometabolic care, creating opportunities in oral drugs, next-gen agonists, biosimilars, manufacturing and Asia-Pacific.

Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

GLP-1 Therapies Market to Reach USD 254.19 Billion by 2034, Driven by Obesity and Type 2 Diabetes Demand

The global GLP-1 therapies market was valued at an estimated USD 62.83 billion in 2025 and is projected to reach USD 254.19 billion by 2034, expanding at a compound annual growth rate of 16.8% from 2026 to 2034. Market growth is being supported by rising obesity and type 2 diabetes prevalence, strong demand for semaglutide- and tirzepatide-based products, broader therapeutic indications, and the commercialization of oral GLP-1 formulations.

GLP-1 Therapies Market Highlights

Biologics led the market by molecule type, accounting for 74% of revenue in 2025.
GLP-1 receptor agonists held a 57% share of the market by drug class.
Semaglutide was the leading active ingredient, representing 43% of market revenue.
Subcutaneous injections dominated the route-of-administration segment with an 82% share.
Type 2 diabetes remained the largest therapeutic application, accounting for 51% of the market.
North America led the global GLP-1 therapies market with a 58% revenue share.
Asia-Pacific is expected to record the fastest regional growth through 2034.

Major GLP-1 Therapies Market Growth Drivers

The increasing global burden of obesity and type 2 diabetes remains the principal driver of GLP-1 therapies market growth. Aging populations, lifestyle changes, and higher diagnosis rates are expanding the addressable patient population across developed and emerging economies. Clinical guidelines are also supporting earlier use of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for glycemic control, chronic weight management, and cardiometabolic risk reduction.

Strong commercial performance is accelerating investment throughout the sector. Novo Nordisk reported DKK 152.2 billion in total GLP-1 sales in 2025, while Eli Lilly's Mounjaro and Zepbound generated combined revenue of approximately USD 36.5 billion. These results demonstrate substantial patient and physician demand while encouraging geographic expansion, manufacturing investment, and development of next-generation therapies.

Oral formulations represent another important market catalyst. The 2026 introduction of once-daily oral products is expected to improve convenience and expand access among patients who prefer alternatives to injectable therapies. Continued development of small-molecule candidates may also offer manufacturing, distribution, and scalability advantages.

The late-stage pipeline includes single, dual, and triple agonists targeting obesity, diabetes, cardiovascular disease, metabolic liver disease, and other related conditions. Candidates such as retatrutide and survodutide illustrate the industry's focus on greater efficacy, improved dosing convenience, and broader clinical utility. Regulatory label expansions covering cardiovascular risk reduction and obstructive sleep apnea are also increasing the eligible patient population.

Market Restraints and Commercial Challenges

Despite strong growth prospects, the GLP-1 therapies market faces high treatment costs, inconsistent reimbursement, adherence challenges, and manufacturing constraints. Access remains uneven outside major developed markets, particularly where public insurance programs do not broadly cover obesity medicines. Gastrointestinal tolerability, injection burden, and out-of-pocket costs may also contribute to treatment discontinuation.

Complex peptide manufacturing and fill-finish requirements have caused periodic supply shortages, while counterfeit and unauthorized compounded products have created additional safety and regulatory concerns. Patent expirations for established active ingredients are expected to increase generic and biosimilar competition, potentially placing pressure on branded pricing. Cold-chain requirements for injectable products and the need for additional long-term outcomes data for newer dual and triple agonists may further influence adoption.

GLP-1 Therapies Market Segment Analysis

Biologics accounted for 74% of the market in 2025, supported by the established commercial presence of semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and tirzepatide. Small molecules are expected to achieve faster growth as oral candidates advance through regulatory and commercial pipelines.

GLP-1 receptor agonists led the drug-class segment with a 57% share, reflecting their broad regulatory footprint and established use across diabetes, obesity, and cardiovascular risk reduction. Dual GIP/GLP-1 receptor agonists are gaining market share rapidly due to the commercial performance of tirzepatide and demand for therapies associated with substantial weight reduction.

Subcutaneous injections represented 82% of revenue in 2025 and are expected to remain the leading administration route in the near term. However, oral products are projected to expand rapidly by reducing injection-related barriers and improving treatment convenience.

Type 2 diabetes generated 51% of market revenue in 2025. Obesity and chronic weight management are expected to represent a growing proportion of future sales, while cardiovascular risk reduction and obstructive sleep apnea provide additional expansion opportunities.

Regional Market Outlook

North America accounted for 58% of global GLP-1 therapies market revenue in 2025. The region benefits from high obesity and diabetes prevalence, established commercial operations, early product launches, expanding payer coverage, advanced clinical-trial infrastructure, and substantial investment in domestic manufacturing capacity. The United States remains the primary contributor, while Canada and Mexico offer additional growth opportunities.

Asia-Pacific is forecast to be the fastest-growing regional market. Rising diagnosis rates, healthcare investment, local drug development, and expanding generic and biosimilar manufacturing are supporting growth across China, Japan, India, South Korea, and Australia. China is becoming an important center for GLP-1 licensing and clinical development, while India is expanding lower-cost pharmaceutical production capacity.

Europe remains a significant market, supported by established regulatory systems and clinical-research capabilities. Adoption varies by country because reimbursement policies for obesity treatment remain uneven. Latin America, the Middle East, and Africa are emerging opportunities as obesity prevalence rises and private-pay, telehealth, and public healthcare channels develop.

Competitive Landscape

The GLP-1 therapies market is concentrated, with Novo Nordisk and Eli Lilly and Company holding leading positions through major injectable and oral franchises. Competition is intensifying as established pharmaceutical companies, biotechnology developers, and generic manufacturers pursue next-generation candidates, regional licensing agreements, and biosimilar products.

Key companies active in the market include:

Novo Nordisk
Eli Lilly and Company
AstraZeneca
Sanofi
Amylin Pharmaceuticals
GlaxoSmithKline
Alvogen
Jiangsu Hansoh Pharmaceutical Group
Shanghai Benemae Pharmaceutical
Hangzhou Jiuyuan Gene Engineering

Competitive priorities include oral formulation development, dual and triple agonist pipelines, manufacturing scale, geographic reach, regulatory label expansion, and strategic licensing. Partnerships involving Chinese biotechnology companies are broadening global pipelines, while investment in peptide synthesis and fill-finish capacity is becoming an increasingly important competitive advantage.

GLP-1 Therapies Market Segmentation

Molecule type: Biologics and small molecules
Drug class: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists
Active ingredient: Semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, and orforglipron
Route of administration: Subcutaneous injections and oral formulations
Therapeutic application: Type 2 diabetes, obesity and chronic weight management, cardiovascular risk reduction, and obstructive sleep apnea
Geography: North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa

Market Outlook

The convergence of rising metabolic disease prevalence, strong commercial demand, oral formulation innovation, pipeline expansion, and broader regulatory indications is expected to sustain double-digit growth in the global GLP-1 therapies market through 2034. Although affordability, reimbursement, adherence, and supply constraints remain important challenges, continued investment in manufacturing and next-generation drug development is positioned to expand access and reshape the global diabetes and obesity treatment landscape.

Key Topics Covered:

1. GLP-1 Therapies Market Report Introduction
1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. GLP-1 Therapies Market Executive Summary
2.1 Market at a Glance

3. GLP-1 Therapies Market Key Factors Analysis
3.1 GLP-1 Therapies Market Drivers
3.1.1 Blockbuster Commercial Performance of Incretin-Based Therapies
3.1.2 Rising Global Burden of Obesity and Type 2 Diabetes
3.1.3 Arrival of Oral GLP-1 Formulations
3.1.4 Deep Late-Stage Pipeline of Next-Generation Agonists
3.2 GLP-1 Therapies Market Restraints and Challenges
3.2.1 Cost, Reimbursement, and Access Barriers
3.2.2 Adherence, Supply, and Manufacturing Constraints
3.2.3 Patent Expiry and Biosimilar Competition
3.3 GLP-1 Therapies Market Opportunities
3.3.1 Oral Small-Molecule and Dual/Triple Agonist Scale-Up
3.3.2 Emerging-Market and Biosimilar Manufacturing Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis
5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. GLP-1 Therapies Market Porter's Five Forces Analysis
6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. GLP-1 Therapies Market Assessment
7.1 By Molecule Type
7.1.1 Biologics
7.1.2 Small Molecules
7.2 By Drug Class
7.2.1 GLP-1 Receptor Agonists
7.2.2 Dual GIP/GLP-1 Receptor Agonists
7.3 By Active Ingredients
7.3.1 Semaglutide
7.3.2 Liraglutide
7.3.3 Dulaglutide
7.3.4 Exenatide
7.3.5 Lixisenatide
7.3.6 Tirzepatide
7.3.7 Orforglipron
7.4 By Route of Administration
7.4.1 Subcutaneous Injections
7.4.2 Oral
7.5 By Therapeutic Application
7.5.1 Type 2 Diabetes
7.5.2 Obesity/Chronic Weight Management
7.5.3 Cardiovascular Risk Reduction
7.5.4 Obstructive Sleep Apnea
7.6 By Geography
7.6.1 North America
7.6.1.1 United States GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.1.2 Canada GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.1.3 Mexico GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2 Europe
7.6.2.1 Germany GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2.2 United Kingdom GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2.3 France GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2.4 Italy GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2.5 Spain GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.2.6 Rest of Europe GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3 Asia-Pacific
7.6.3.1 China GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3.2 Japan GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3.3 India GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3.4 Australia GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3.5 South Korea GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.3.6 Rest of Asia-Pacific GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.4 Rest of World
7.6.4.1 Middle East GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.4.2 Africa GLP-1 Therapies Market Size in USD million (2023-2034)
7.6.4.3 South America GLP-1 Therapies Market Size in USD million (2023-2034)

8. GLP-1 Therapies Market Competitive Landscape
8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. GLP-1 Therapies Market Startup Funding and Investment Trends

10. GLP-1 Therapies Market Company and Product Profiles
10.1 Novo Nordisk
10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Financial Overview
10.1.4 Service Portfolio
10.1.5 Strategic Initiatives / Entropy
10.2 Eli Lilly and Company
10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Financial Overview
10.2.4 Product Portfolio
10.2.5 Strategic Initiatives / Entropy
10.3 AstraZeneca
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Financial Overview
10.3.4 Product Portfolio
10.3.5 Strategic Initiatives / Entropy
10.4 Sanofi
10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Financial Overview
10.4.4 Product Portfolio
10.4.5 Strategic Initiatives / Entropy
10.5 Amylin Pharmaceuticals
10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Financial Overview
10.5.4 Product Portfolio
10.5.5 Strategic Initiatives / Entropy
10.6 GlaxoSmithKline (GSK)
10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Financial Overview
10.6.4 Product Portfolio
10.6.5 Strategic Initiatives / Entropy
10.7 Alvogen
10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Financial Overview
10.7.4 Product Portfolio
10.7.5 Strategic Initiatives / Entropy
10.8 Jiangsu Hansoh Pharmaceutical Group
10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Financial Overview
10.8.4 Product Portfolio
10.8.5 Strategic Initiatives / Entropy
10.9 Shanghai Benemae Pharmaceutical
10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Financial Overview
10.9.4 Product Portfolio
10.9.5 Strategic Initiatives / Entropy

10. Hangzhou Jiuyuan Gene Engineering
10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About the Publisher

14. Disclaimer and Contact Us

List of Tables
Table 1: GLP-1 Therapies Market in Global (2023-2034)
Table 2: GLP-1 Therapies Market in Global by Molecule Type (2023-2034)
Table 3: GLP-1 Therapies Market in Global by Drug Class (2023-2034)
Table 4: GLP-1 Therapies Market in Global by Active Ingredients (2023-2034)
Table 5: GLP-1 Therapies Market in Global by Route of Administration (2023-2034)
Table 6: GLP-1 Therapies Market in Global by Therapeutic Applications (2023-2034)
Table 7: GLP-1 Therapies Market in Global by Geography (2023-2034)
Table 8: GLP-1 Therapies Market in North America (2023-2034)
Table 9: GLP-1 Therapies Market in the United States (2023-2034)
Table 10: GLP-1 Therapies Market in Canada (2023-2034)
Table 11: GLP-1 Therapies Market in Mexico (2023-2034)
Table 12: GLP-1 Therapies Market in Europe (2023-2034)
Table 13: GLP-1 Therapies Market in Germany (2023-2034)
Table 14: GLP-1 Therapies Market in United Kingdom (2023-2034)
Table 15: GLP-1 Therapies Market in France (2023-2034)
Table 16: GLP-1 Therapies Market in Italy (2023-2034)
Table 17: GLP-1 Therapies Market in Spain (2023-2034)
Table 18: GLP-1 Therapies Market in the Rest of Europe (2023-2034)
Table 19: GLP-1 Therapies Market in Asia-Pacific (2023-2034)
Table 20: GLP-1 Therapies Market in China (2023-2034)
Table 21: GLP-1 Therapies Market in Japan (2023-2034)
Table 22: GLP-1 Therapies Market in India (2023-2034)
Table 23: GLP-1 Therapies Market in Australia (2023-2034)
Table 24: GLP-1 Therapies Market in South Korea (2023-2034)
Table 25: GLP-1 Therapies Market in Rest of Asia-Pacific (2023-2034)
Table 26: GLP-1 Therapies Market in the Rest of the World (2023-2034)
Table 27: GLP-1 Therapies Market in the Middle East (2023-2034)
Table 28: GLP-1 Therapies Market in Africa (2023-2034)
Table 29: GLP-1 Therapies Market in South America (2023-2034)
Table 30: Competitive Landscape
Table 31: Startup Funding and Investment Trends

List of Figures
Figure 1: GLP-1 Therapies Market Drivers
Figure 2: GLP-1 Therapies Market Restraints
Figure 3: GLP-1 Therapies Market Opportunities
Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
Figure 5: Regulatory Analysis (US, EU, Japan, China)
Figure 6: Porter's Five Forces Analysis
Figure 7: Competitive Analysis
Figure 8: GLP-1 Therapies Market in Global (2023-2034)
Figure 9: GLP-1 Therapies Market in Global by Molecule Type (2023-2034)
Figure 10: GLP-1 Therapies Market in Global by Drug Class (2023-2034)
Figure 11: GLP-1 Therapies Market in Global by Active Ingredients (2023-2034)
Figure 12: GLP-1 Therapies Market in Global by Route of Administration (2023-2034)
Figure 13: GLP-1 Therapies Market in Global by Therapeutic Applications (2023-2034)
Figure 14: GLP-1 Therapies Market in Global by Geography (2023-2034)
Figure 15: GLP-1 Therapies Market in North America (2023-2034)
Figure 16: GLP-1 Therapies Market in the United States (2023-2034)
Figure 17: GLP-1 Therapies Market in Canada (2023-2034)
Figure 18: GLP-1 Therapies Market in Mexico (2023-2034)
Figure 19: GLP-1 Therapies Market in Europe (2023-2034)
Figure 20: GLP-1 Therapies Market in Germany (2023-2034)
Figure 21: GLP-1 Therapies Market in United Kingdom (2023-2034)
Figure 22: GLP-1 Therapies Market in France (2023-2034)
Figure 23: GLP-1 Therapies Market in Italy (2023-2034)
Figure 24: GLP-1 Therapies Market in Spain (2023-2034)
Figure 25: GLP-1 Therapies Market in the Rest of Europe (2023-2034)
Figure 26: GLP-1 Therapies Market in Asia-Pacific (2023-2034)
Figure 27: GLP-1 Therapies Market in China (2023-2034)
Figure 28: GLP-1 Therapies Market in Japan (2023-2034)
Figure 29: GLP-1 Therapies Market in India (2023-2034)
Figure 30: GLP-1 Therapies Market in Australia (2023-2034)
Figure 31: GLP-1 Therapies Market in South Korea (2023-2034)
Figure 32: GLP-1 Therapies Market in Rest of Asia-Pacific (2023-2034)
Figure 33: GLP-1 Therapies Market in the Rest of the World (2023-2034)
Figure 34: GLP-1 Therapies Market in the Middle East (2023-2034)
Figure 35: GLP-1 Therapies Market in Africa (2023-2034)
Figure 36: GLP-1 Therapies Market in South America (2023-2034)
Figure 37: Competitive Landscape
Figure 38: Startup Funding and Investment Trends

A selection of companies mentioned in this report includes, but is not limited to:

Novo Nordisk
Eli Lilly and Company
AstraZeneca
Sanofi
Amylin Pharmaceuticals
GlaxoSmithKline (GSK)
Alvogen
Jiangsu Hansoh Pharmaceutical Group
Shanghai Benemae Pharmaceutical
Hangzhou Jiuyuan Gene Engineering

For more information about this report visit https://www.researchandmarkets.com/r/y3y5sw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

GLP-1 Therapies Market Set for Rapid Growth Through 2034 as Obesity and Diabetes Demand, Drug Innovation, and Expanding Indications Fuel New Business Opportunities